TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03414502
Drug: Azathioprine
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Starting dose which may be adjusted as needed at the discretion of the investigator
Study: NCT03414502
Drug: Minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Starting dose which may be adjusted as needed at the discretion of the investigator
Study: NCT02106598
Drug: fluorescent cRGDY-PEG-Cy5.5-C dots
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04073173
Drug: Analgesic, Opioid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil (0.5-2 micrograms/kg/dose)
Study: NCT02273479
Drug: Asasantin®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Asasantin® extended release (RAD-SP)
Study: NCT02273479
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01423175
Drug: FLAMSA
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03554109
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: L-Glutamic acid, N-\[4-\[\[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl\]amino\]benzoyl\]-, calcium salt
Study: NCT00007254
Drug: Pain relief for pressure ulcers
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03554109
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
Study: NCT03554109
Drug: Doxorubicin HCL
Normalized name: doxorubicin HCl
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin HCL
Study: NCT03175666
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
Study: NCT01972217
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo bid
Study: NCT02799446
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo intravenous (IV)
Study: NCT04240535
Drug: OnabotulinumtoxinA 50 UNT [Botox Cosmetic]
Normalized name: onabotulinumtoxinA 50 UNT [Botox Cosmetic]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injections to the Depressor Anguli Oris
Study: NCT03175666
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
Study: NCT03175666
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Calcium N-\[p-\[\[\[(6RS)-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl\]methyl\]amino\]benzoyl\]-L-glutamate (1:1)
Study: NCT01407432
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Taking of folic acid 15 mg per day by hanging oral route during 3 at 4 months
Study: NCT01407432
Drug: placebo of folic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taking of placebo of folic acid by hanging oral route during 3 at 4 months
Study: NCT03703700
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients who undergo the long-term protocol will start taking Placebo on the day of pituitary suppression, 5g three times a day (Stopping on the first 1-4 days of menstruation), and patients who undergo the antagonist protocol will start taking Placebo on the 19th to 23rd day of the previous menstruation cycle, 5g three times a day (Stopping on the first 1-4 days of menstruation). The drug will be taken till 2 weeks after transplantation. If the test result is confirmed as biochemical pregnancy (HCG\>50 IU/L), patients continue to take pills till 3 weeks after the clinical pregnancy determined by the ultrasound. If it is determined that the pregnancy test is negative, stop the drug.
Study: NCT02170376
Drug: BIA 9-1067
Normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIA 9-1067 25 mg and 50 mg
Study: NCT02170376
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: PLC, placebo
Study: NCT02170376
Drug: Levodopa/carbidopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levodopa/carbidopa, tablet 100/25 mg
Study: NCT00578539
Drug: ARA C
Normalized name: Toxocara cati Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ara C (3000 mg/m2) IV every 12 hours for 6 doses (days -8 to -5)
Study: NCT00578539
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide (45mg/kg) IV once daily on day -7 and day -6
Study: NCT02166346
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pill 1 tablet twice daily for 8 weeks
Study: NCT02536976
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04424134
Drug: Bromhexine and Spironolactone
Normalized name: bromhexine
DrugBank: Bromhexine (DB09019)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromhexine 8 mg x 4 times a day x 10 days Spironolactone 50 mg x once a day x 10 days
Study: NCT04424134
Drug: Base therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapy currently recommended by Ministry of Health of Russian Federation for COVID 19 treatment
Study: NCT02289586
Drug: sedation(dezocine and midazolam)
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02289586
Drug: general anesthesia(midazolam, fentanyl，rocuronium，propofol and Remifentanil）
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03085004
Drug: Ethanol
Normalized name: Ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The cyst will be lavaged for 3 to 5 minutes using \>/=99% ethanol as the lavage agent prior to infusing the cyst with the paclitaxel + gemcitabine admixture.
Study: NCT03085004
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: The cyst will be lavaged for 3 to 5 minutes using normal saline as the lavage agent prior to infusing the cyst with the paclitaxel + gemcitabine admixture.
Study: NCT00222612
Drug: Standard childhood UK ALL protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: No additional treatment to standard protocol.
Study: NCT00222612
Drug: Intensified treatment including Capizzi maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Augmented consolidation: vincristine, Peg-asparaginase. Capizzi maintenance: iv methotrexate and peg-asparaginase
Study: NCT00707083
Drug: mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally
Study: NCT00707083
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given orally
Study: NCT03738878
Drug: LCZ696
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral LCZ696
Study: NCT02706977
Drug: Low Dose Sinemet CR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sinemet CR (25 mg carbidopa/100 mg levodopa) will be taken by mouth twice daily for two weeks.
Study: NCT02706977
Drug: High Dose Sinemet CR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sinemet CR (50 mg carbidopa/200 mg levodopa) will be taken by mouth twice daily for two weeks.
Study: NCT00945958
Drug: SPARC0913
Approvals — FDA: no, EMA: no, PMDA: no
Description: One drop of SPARC0913 in affected eye once daily for 24 weeks
Study: NCT00002534
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01590719
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeating intravenous dose until disease progression, unacceptable toxicity, or patient or physician decision to discontinue treatment
Study: NCT04238923
Drug: Topical vancomycin paste (1g vancomycin powder + 4mL sterile saline) and Collatamp G gentamicin-eluting sponge (Azralez Pharmaceuticals; 2.0mg gentamicin sulphate/cm2 to cover wound)
Normalized name: gentamicin Topical Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical vancomycin paste and gentamicin-eluting collagen sponge will be applied directly to the deep layers of the wound following reconstruction, prior to closure.
Study: NCT01317472
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet of placebo QAM (1 hour AC) for 2 months
Study: NCT04176198
Drug: Nusivertib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral PIM Inhibitor
Study: NCT01354964
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02584686
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: The control group, 12 patients, will be injected with a trimix solution during penile colour Doppler assessment followed next day with a normal saline injection.
Study: NCT00620451
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: gelatin capsule
Study: NCT00129402
Drug: ezetimibe with simvastatin
Normalized name: ezetimibe / simvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe 10 mg plus simvastatin 10 mg once a day for six weeks, or Ezetimibe 10 mg plus simvastatin 20 mg once a day for six weeks, or Ezetimibe 10 mg plus simvastatin 40 mg once a day for six weeks
Study: NCT00129402
Drug: simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ezetimibe matching placebo plus simvastatin 10 mg once a day for six weeks, or Ezetimibe matching placebo plus simvastatin 20 mg once a day for six weeks, or Ezetimibe matching placebo plus simvastatin 40 mg once a day for six weeks
Study: NCT01285323
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo (acetate sucrose buffer), administered intravenously (iv) once every 4 weeks for a total of 13 doses.
Study: NCT03149679
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Chemotherapy
Study: NCT03915886
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablets will be administered orally.
Study: NCT02630823
Drug: MK-3475
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03715114
Drug: GV-971
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral GV-971
Study: NCT03715114
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Placebo
Study: NCT04178733
Drug: LY3493269 - SC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT04178733
Drug: Placebo - SC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT04178733
Drug: LY3493269 - IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV
Study: NCT02736448
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral low dose of capecitabine
Study: NCT02736448
Drug: SS-LAR
Approvals — FDA: no, EMA: no, PMDA: no
Description: long acting octreotide or lanreotide
Study: NCT02395367
Drug: neoadjuvant chemotherapy or adjuvant chemotherapy
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is an observational study. And we are interested in observing the outcome of different treatment methods.
Study: NCT03940950
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline control that contains no active ingredient
Study: NCT03169764
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
Study: NCT03169764
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
Study: NCT03169764
Drug: leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Calcium N-\[p-\[\[\[(6RS)-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl\]methyl\]amino\]benzoyl\]-L-glutamate (1:1)
Study: NCT03391466
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered intravenously
Study: NCT01974245
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 drops/ week for 12 weeks
Study: NCT03785873
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous (IV) infusion
Study: NCT03442413
Drug: 2-[18F]-FA PET/CT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-\[18F\]FA is a highly specific radiotracer which has been used successfully to image nicotinic acetylcholine receptors in the human brain to characterize the effects of nicotine exposure (via smoking) on these receptors.
Study: NCT03939143
Drug: DA-1229_01(A), Sugamet SR Tab 5/1000mg®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Period 1: Single oral administration of 1 tablet of test drug together with 150 mL of water containing 30 g sugar.~The wash-out for fed study is 14 days. Period 2: Single oral administration of 1 tablet of reference drug together with 150 mL of water containing 30 g sugar.
Study: NCT03939143
Drug: Sugamet SR Tab 5/1000mg®, DA-1229_01(A)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Period 1: Single oral administration of 1 tablet of reference drug together with 150 mL of water containing 30 g sugar.~The wash-out for fed study is 14 days. Period 2: Single oral administration of 1 tablet of test drug together with 150 mL of water containing 30 g sugar.
Study: NCT02992288
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally once daily for 20 weeks
Study: NCT04636125
Drug: Doxycycline 100 MG Oral Tablet
Normalized name: DOXYCYCLINE 100 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients that are undergoing a single stage revision total shoulder arthroplasty will be enrolled in this study. As is standard of care, routine cultures will be taken from predetermined areas in the shoulder. All patients will be treated with 13 days of oral Doxycycline pending culture results.
Study: NCT03505762
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03505762
Drug: Doxorubicin Hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT02991222
Drug: SPARC001 type I
Normalized name: collagen type I
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment type I
Study: NCT02991222
Drug: SPARC001 type II
Normalized name: collagen type II
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment type II
Study: NCT02991222
Drug: Reference001 type I
Normalized name: collagen type I
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocodone-Acetaminophen
Study: NCT02991222
Drug: Reference001 type II
Normalized name: collagen type II
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocodone-Acetaminophen
Study: NCT00003042
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003042
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04214990
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily placebo for 5 years
Study: NCT04558125
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match supplied by Genentech, Inc. as a sterile, lyophilized powder, diluted with 10mL sterile water.
Study: NCT01185236
Drug: simvastatin/ezetimibe
Approvals — FDA: no, EMA: no, PMDA: no
Description: simvastatin/ezetimibe 10/20mg once daily for 12weeks
Study: NCT00801957
Drug: hydrocortisone butyrate ointment 0.1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical application
Study: NCT03130738
Drug: 14-Day Placebo - Oil Vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14 days of 2x per day treatment with Placebo - Oil Vehicle, Study Drug base without active ingredient
Study: NCT01033019
Drug: LDE225 0.75%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75% cream
Study: NCT01033019
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo cream to 0.75% LDE225 cream
Study: NCT00817843
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 6 weeks of treatment with simvastatin 80 mg
Study: NCT00817843
Drug: Simvastatin/Ezetimibe
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 weeks of treatment with simvastatin 10 mg / ezetimibe 10 mg combination
Study: NCT03931941
Drug: RBX2660
Approvals — FDA: no, EMA: no, PMDA: no
Description: RBX2660 is a microbiota suspension administered as an enema
Study: NCT03476642
Drug: Epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: injection of 20mL epinephrine in combination with ropivacaine at the left or right T5 transverse process
Study: NCT03982121
Drug: FOLFOX regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxaliplatin 85 mg/m² Leucovorin (LV) levogyre form (LLV) 200 mg/m² or dextro-levogyre (DL-LV) racemic mixture 400 mg/m²) Fluorouracil 2400 mg/m²
Study: NCT00563875
Drug: acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75 mg/d for 7 days (healthy volunteers) and continued treatment with 75 mg/d in patients taking daily aspirin.
Study: NCT01569191
Drug: Anti-allergic Medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 drop on single occasion after exposure to grass pollen
Study: NCT03809702
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pain score in group 1 (intervention group) will be compared with pain score in group 2 (placebo group)
Study: NCT02285699
Drug: SSRIs
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12-weeks of standard SSRi treatment for those interested in Phase II of the study.
Study: NCT00499733
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 500 mg/m\^2 of cyclophosphamide is infused via intravenous route three days post cryoablation surgery.
Study: NCT03931928
Drug: (Z)-Endoxifen supplementation according to genotype
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 2: CYP2D6 genotype predicted intermediate metabolizer receive 1.5 mg, poor metabolizer receive 3 mg (Z)-Endoxifen and extensive or ultrarapid metabolizer receive 0 mg endoxifen (Placebo)
Study: NCT00532233
Drug: QAX576
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00635804
Drug: MK-3281
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-3281 capsule administered orally BID for 7 or 10 consecutive days depending on randomized dose. The PM dose of MK-3281 was not administered on Day 7 (for HCV-infected males) or Day 10 (for healthy males)
Study: NCT00635804
Drug: Placebo to MK-3281
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-matched placebo to MK-3281 capsule administered orally BID for 7 or 10 consecutive days depending on randomized dose of MK-3281 in serial panel. The PM dose of matched placebo was not administered on Day 7 or 10 (depending upon allocation).
Study: NCT00612573
Drug: Doxycycline 0.6 mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: doxycycline 40 mg/day, oral, 12 weeks
Study: NCT00612573
Drug: Doxycycline 1.2 mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: doxycycline 80 mg/day, 12 weeks
Study: NCT00612573
Drug: Doxycycline 2.4 mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: doxycycline 160 mg/day, 12 weeks
Study: NCT00612573
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, 12 weeks
Study: NCT03606018
Drug: Humalog® Mix 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: insulin lispro biphasic in doses 0.4 ME/kg
Study: NCT03371667
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate 5 mg/m2 will be given once week for 4 weeks, then 3 mg/m2 every two weeks for 12 weeks. Body surface area will be capped at 2 m2.~Methotrexate will be given as an IV infusion over 15 minutes. All patients will received prednisone 2 mg/kg.day PO (or methylprednisolone 1.6 mg/Kg/day) for 3 days.~For responding patients between day 4 and 28, the dose of prednisone must be at least 0.25 mg/kg/day prednisone (or 0.2 mg/kg/day methylprednisolone).~All patients should receive a folinic acid supplementation 24 hours after each MTX/placebo administration.~Lederfoldin 10 mg po or iv will be administered on days 2, 9, 16 and 23. Lederfoldin 10 mg po or iv will be administered on days 37, 51, 65, 79, 93 and 103.
Study: NCT04318015
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: All placebo will be administered orally
Study: NCT03371667
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 5 mg/m2 will be given once week for 4 weeks, then 3 mg/m2 every two weeks for 12 weeks. Body surface area will be capped at 2 m2.~Placebo will be given as an IV infusion over 15 minutes. All patients will received prednisone 2 mg/kg.day PO (or methylprednisolone 1.6 mg/Kg/day) for 3 days.~For responding patients between day 4 and 28, the dose of prednisone must be at least 0.25 mg/kg/day prednisone (or 0.2 mg/kg/day methylprednisolone).~All patients should receive a folinic acid supplementation 24 hours after each MTX/placebo administration.~Lederfoldin 10 mg po or iv will be administered on days 2, 9, 16 and 23. Lederfoldin 10 mg po or iv will be administered on days 37, 51, 65, 79, 93 and 103.
Study: NCT02701374
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00568022
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine: Tablets, Oral, 1650(2000)mg/m\^2, twice daily for 2 weeks, one week off, up to 6 cycles
Study: NCT04522635
Drug: (100 ml of Albumin 25%)
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose of 25g albumin (100 ml of Grifols 25%) given intravenously at the start of IHD
Study: NCT00167713
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02516605
Drug: Part 1: LJN452
Approvals — FDA: no, EMA: no, PMDA: no
Description: LJN452 capsules administered once daily for 28 days